HOME › DRUGS › BASILIXIMAB
ACTIVE SUBSTANCE / INN

BASILIXIMAB

Brand name(s): Simulect, SIMULECT
FDA LISTED
EMA LISTED
PRESCRIPTION
AUTHORISED
BLA103764
Graft Rejection;Kidney Transplantation
ACTIVE SUBSTANCE
Basiliximab
REGULATORS
FDA · EMA
SPONSORS / MAH
NOVARTIS, Novartis Europharm Limited
TOTAL APPLICATIONS
2
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
SIMULECTBLA103764NOVARTISPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
SimulectNovartis Europharm LimitedAuthorised09/10/1998Graft Rejection;Kidney Transplantation

FULL INTELLIGENCE ON BASILIXIMAB

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →